Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04608448 · ClinicalTrials.gov registry record · Early Phase 1
Topical-RAPA Use in Inflammation Reversal and Re-setting the Epigenetic Clock
A Early Phase 1 study of Aging and Epigenetics, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT04608448: Completed Early Phase 1 study of Aging and Epigenetics, sponsored by The University of Texas Health Science Center at San Antonio.
NCT04608448 is a Early Phase 1 study of Aging and Epigenetics that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 22 participants, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04608448, a Early Phase 1 study of Aging and Epigenetics, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
Topical Rapamycin ointment will be applied to participant forearms to test whether epigenetic changes in the skin are elicited.
Primary Outcome
A set of DNA methylation marks that correlate with chronological age will be used to measure rejuvenation of the "epigenetic clock" due to drug treatment compared to placebo. Using Illumina EPIC arrays, CpG methylation will be assessed and then the predicted age, based on the combined methylation at the set of 391 marks (the "epigenetic clock" as defined by Dr. Steven Horvath, UCLA), will be determined.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Rapamycin Topical Ointment
Study Locations (1)
Texas
- UTHSCSA - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2021-04-28 |
| Est. Completion | 2022-04-15 |
| Phase | Early Phase 1 |
What the finished NCT04608448 record still lists
NCT04608448 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Aging appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04608448 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04608448 about?
NCT04608448 is a clinical study titled "Topical-RAPA Use in Inflammation Reversal and Re-setting the Epigenetic Clock". Topical Rapamycin ointment will be applied to participant forearms to test whether epigenetic changes in the skin are elicited.
What is the current status of trial NCT04608448?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 22 participants. The study started on 2021-04-28. Estimated completion is 2022-04-15.
What conditions does trial NCT04608448 study?
This clinical trial studies the following conditions: Aging, Epigenetics, Inflammatory Mediators.
What interventions are being tested in trial NCT04608448?
The interventions under investigation include: Placebo (OTHER), Rapamycin Topical Ointment (DRUG).
Who is sponsoring clinical trial NCT04608448?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04608448 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04608448's enrollment target sits among peer trials
22 226th of 262 higher than 33 of 262 other Aging trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Aging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gene Expression Changes In Young and Geriatric Skin
RECRUITING · Early Phase 1
-
Examining the Effects of Theta Burst TMS on Brain Connectivity and Balance Ability in Older Adults With Balance Problems
RECRUITING · Early Phase 1
-
Transient Receptor Potential Channels
RECRUITING · Early Phase 1
-
Early Neurovascular Adaptations in Aging Women
RECRUITING · Early Phase 1
-
Heat, Microvascular Function and Aging
RECRUITING · Early Phase 1
-
Angiotensin-(1-7) Cardiovascular Effects in Aging
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI